15-088
Showing 1 - 25 of >10,000
Healthy Volunteers Trial in Gières, Marseille (IFB-088 (2.5-60.0mg) oral capsule, Placebo (2.5-60.mg) oral capsule, IFB-088
Completed
- Healthy Volunteers
- IFB-088 (2.5-60.0mg) oral capsule
- +3 more
-
Gières, France
- +1 more
Nov 18, 2021
Lyme Disease Trial in Worldwide (VLA15, Saline)
Not yet recruiting
- Lyme Disease
- VLA15
- Saline
-
New London, Connecticut
- +25 more
Aug 2, 2022
Postmenopausal Osteoporosis Trial in Worldwide (FKS518, US-licensed Prolia)
Active, not recruiting
- Postmenopausal Osteoporosis
- FKS518
- US-licensed Prolia
-
Sofia, Sofia City, Bulgaria
- +75 more
Aug 29, 2022
Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.1 GBq (30 mCi) of 177Lu-P17-087, 1.1 GBq (30 mCi) of
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
- 1.1 GBq (30 mCi) of 177Lu-P17-087
- 1.1 GBq (30 mCi) of 177Lu-P17-088
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Oct 30, 2022
Eczema, Atopic Dermatitis Trial in Worldwide (KY1005, Placebo)
Active, not recruiting
- Eczema
- Atopic Dermatitis
- KY1005
- Placebo
-
Fremont, California
- +102 more
Dec 13, 2022
Nasal Polyps, Chronic Rhinosinusitis Trial in Worldwide (Omalizumab, Placebo)
Completed
- Nasal Polyps
- Chronic Rhinosinusitis
- Omalizumab
- Placebo
-
Birmingham, Alabama
- +78 more
Mar 31, 2022
Hypertension Trial in Worldwide (Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5
Recruiting
- Hypertension
- Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
- +7 more
-
Phoenix, Arizona
- +84 more
Aug 19, 2022
Diabetes, Type 2 Trial in Worldwide (NNC0480-0389, Semaglutide, Placebo (NNC080-0389))
Recruiting
- Diabetes Mellitus, Type 2
- NNC0480-0389
- +3 more
-
Buena Park, California
- +95 more
Mar 31, 2022
Overweight, Overweight and Obesity, Overweight or Obesity Trial in New York (Counseling, Text Messages, Phone calls)
Recruiting
- Overweight
- +4 more
- Counseling
- +3 more
-
New York, New YorkMexican Consulate's Ventanilla de Salud (VDS)
Mar 20, 2023
Pain Trial in Heerlen (Virtual reality intervention performed through the Oculuc Go VR glasses)
Recruiting
- Pain
- Virtual reality intervention performed through the Oculuc Go VR glasses
-
Heerlen, NetherlandsZuyderaland MC
Feb 22, 2023
NSCLC Trial in Netherlands (Durvalumab, low-dose PCI)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Durvalumab
- low-dose PCI
-
Almelo, Netherlands
- +11 more
Feb 1, 2022
Amyotrophic Lateral Sclerosis, ALS Trial in France, Italy (IFB-088 50mg/day, Placebo, Riluzole 100mg/day)
Not yet recruiting
- Amyotrophic Lateral Sclerosis
- ALS
- IFB-088 50mg/day
- +2 more
-
Angers, France
- +19 more
Aug 18, 2022
Psoriatic Arthritis Trial in Worldwide (Apremilast 20mg, Apremilast 30mg, Placebo)
Completed
- Psoriatic Arthritis
- Apremilast 20mg
- +2 more
-
Phoenix, Arizona
- +117 more
May 26, 2022
Asthma Trial in Worldwide (FF/VI via ELLIPTA DPI, FF via ELLIPTA DPI)
Completed
- Asthma
- FF/VI via ELLIPTA DPI
- FF via ELLIPTA DPI
-
Hoover, Alabama
- +183 more
Sep 12, 2022
B-cell Non Hodgkin Lymphoma Trial in Hanzhou (CB dualCAR-NK19/70)
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- CB dualCAR-NK19/70
-
Hanzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 25, 2022
Analgesia Trial in Erzurum (Group Suprainguinal fascia iliaca block, Group Periarticular Infiltration)
Recruiting
- Analgesia
- Group Suprainguinal fascia iliaca block
- Group Periarticular Infiltration
-
Erzurum, TurkeyAli Ahiskalioglu
Nov 23, 2022
aScope Single Use ERCP Study- ASSURE Study
Not yet recruiting
- ERCP
- +2 more
- Endoscopic retrograde Cholangio-pancreatography (ERCP) with aScope (Single use duodenoscope
-
Nottingham, United KingdomNottingham University Hospitals NHS Trust
Feb 4, 2022